Skip to content

PRospective Evaluation of Electrocardiographic Voltage Changes and Six Minute Walk Test for Predicting Readmissions in Heart Failure (PREEMT-HF Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01675544
Acronym
PREEMT-HF
Enrollment
46
Registered
2012-08-30
Start date
2012-08-31
Completion date
2014-06-30
Last updated
2015-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart failure

Brief summary

Purpose of the study: To identify whether Electrocardiographic QRS voltage changes (between admission and pre-discharge) and pre discharge 6- minute walk test in patients admitted with acute heart failure can identify patients at risk for recurrent admissions for heart failure.

Detailed description

Primary Objective Determine the ability of EKG voltage changes and pre discharge 6-minute walk test (6-MWT) to predict repeat heart failure hospitalization (HFH) in patients admitted with acute decompensated heart failure (ADHF). Secondary Objectives 1. Determine the ability of EKG voltage changes and pre discharge 6-MWT) to predict a composite of 1 year mortality and HFH in patients admitted with ADHF. 2. Determine the ability of proportionate pulse pressure, orthostatic blood pressure changes and pre discharge inferior vena cava (IVC) diameter by portable ultrasound to predict HFH and mortality

Interventions

PROCEDUREElectrocardiogram

EKG voltage changes between admission and discharge

Sponsors

Creighton University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \> 18 years of age, admitted with a diagnosis of ADHF and fulfilling the following criteria: 1. Evidence of systemic congestion (manifested by any 2 of the following criteria: jugular venous distension, edema, pulmonary rales, Left ventricular S3, or radiographic evidence of pulmonary venous congestion) 2. Elevated Brain natriuretic peptide 3. Need for at least 1 dose of intravenous loop diuretic

Exclusion criteria

* Cardiogenic shock, Acute coronary syndromes (patients with mild elevation in troponin related to heart failure will not be excluded), patients who are admitted for another principal problem and develop ADHF in the hospital, pregnant females, end stage renal disease on hemodialysis, expected survival \< 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Emergency Room Visit or Hospitalization for Acute Decompensated Heart Failure (ADHF)1 year
Mortality1 yearAll cause mortality at 1 year

Countries

United States

Participant flow

Participants by arm

ArmCount
Heart Failure Admission
Patients admitted for acute decompensated heart failure Electrocardiogram: EKG voltage changes between admission and discharge Six minute walk test
46
Total46

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicHeart Failure Admission
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
24 Participants
Age, Categorical
Between 18 and 65 years
22 Participants
Region of Enrollment
United States
46 participants
Sex: Female, Male
Female
19 Participants
Sex: Female, Male
Male
27 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 46
serious
Total, serious adverse events
0 / 46

Outcome results

Primary

Emergency Room Visit or Hospitalization for Acute Decompensated Heart Failure (ADHF)

Time frame: 1 year

ArmMeasureValue (NUMBER)
Heart Failure AdmissionEmergency Room Visit or Hospitalization for Acute Decompensated Heart Failure (ADHF)20 participants
Primary

Mortality

All cause mortality at 1 year

Time frame: 1 year

ArmMeasureValue (NUMBER)
Heart Failure AdmissionMortality9 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026